Adolescent ; Adult ; Aged ; Aged, 80 and over ; Case-Control Studies ; Child ; Female ; Humans ; Lymphocyte Count ; Male ; Middle Aged ; Myelodysplastic Syndromes ; blood ; T-Lymphocytes, Helper-Inducer ; Young Adult

Anemia, Macrocytic ; Chromosome Deletion ; Chromosomes, Human, Pair 5 ; Cri-du-Chat Syndrome ; Humans ; Trisomy

Animals ; Dust ; Male ; Malondialdehyde ; blood ; Mice ; Nanoparticles ; Oxidation-Reduction ; drug effects ; Particle Size ; Silicon Dioxide ; toxicity ; Superoxide Dismutase ; blood

Objective: To clone the cDNA of human sPLA2-IIA,construct the engineered Escherischia coli expressing human sPLA2-IIA and identify the expressed human sPLA2-IIA. Methods: Total RNAs were purified from human fetal spleen. The cDNA of human sPLA2-IIA was cloned by RT-PCR and inserted into plasmid pET32a(+) between NcoI and EcoRI sites for expressing the recombinant human sPLA2-IIA in Escherischia coli BL21(DE3). The recombinants were screened by SDS-PAGE. The engineered Escherischia coli expressing trxA-human sPLA2-IIA fusion protein was established. The expressed human sPLA2-IIA exists in the form of inclusion body and accounts for about 25% of the total proteins of Escherischia coli BL21(DE3). Conclusion: the engineered E. coli methods are suitable for preparing plenty of human sPLA2-IIA which has laid base for the large-scale expression,purification and basic studies of human sPLA2-IIA.

OBJECTIVETo compare the efficacy on vertebrobasilar insufficiency (VBI) between auricular acupuncture therapy and oral administration of medicine.

METHODSSixty patients of VBI were randomized into an auricular acupuncture therapy group and a medicine group, 30 cases in each one. In the auricular acupuncture group, acupuncture was applied bilaterally to gan (CO12) and jiejie (HX8) on the ears and needles were retained for 15 min. After needle withdrawal, the vaccariae semen were fixed with plaster at naogan (AT3, 4i), zhen (AT3), jing (AH12), shen (CO10) and pi (CO13) on the ears. In the medicine group, flunarizine hydrochloride capsules (Sibelium), 5mg were prescribed for oral administration, once every night. The treatment lasted continuously for 2 weeks (14 days) in the two groups. In 2 weeks, the clinical efficacy was assessed and the transcranial doppler (TCD) examination was performed.

RESULTSAfter treatment, the symptom scores were all apparently reduced in the patients of the two groups (P < 0.01, P < 0.05). Compared with the medicine group, the reduced score was much more obvious in the auricular acupuncture group (P < 0.05), indicating the significant difference. After treatment, with TCD examination, the blood velocity was increased to different degrees in the patients of low velocity type in the auricular acupuncture group and the medicine group; that was reduced to different degrees in the patients of high velocity type in the auricular acupuncture group and the medicine group. All of them were different significantly as compared with those before treatment (all P < 0.05). But the difference was not significant between the two groups (both P > 0.05). In comparison of clinical efficacy between the two groups, the effective rate was 93.3% (28/30) in the acupuncture group and better than 76.7% (23/30) in the medicine group, indicating the significant difference in comparison (P < 0.05).

CONCLUSIONThe auricular acupuncture therapy achieves the definite efficacy on VBI and the efficacy is better than flunarizine hydrochloride capsules.

Acupuncture Points ; Acupuncture, Ear ; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome ; Vertebrobasilar Insufficiency ; therapy

Adenocarcinoma ; pathology ; Aged ; Ear Neoplasms ; pathology ; Endolymphatic Sac ; Humans ; Male

The essence of myelodysplastic syndrome (MDS) is a malignant clonal bone marrow myeloid neoplasm. Both basic researches and clinical studies should firmly grasp this essence of MDS and should not be interferenced by confounding factors. Comprehensive diagnosis can improve the accuracy of MDS diagnosis by multiple indicators that reflect the malignant nature, such as cell dysplasia, function abnormalities, cytogenetic changes and gene mutations. The therapy of MDS should also eradicate the MDS clone, change the disease progression, stimulating normal hematopoiesis, prolong the survival and improve the quality of life.

Myelodysplastic syndromes (MDS) is a kind of bone marrow failure disease. Thrombocytopenia in patients with MDS is a frequent causes of mortality in MDS with 37% to 67% incidence. Thrombocytopenia in MDS is an independent factor predicting worse prognosis associated with increased risk of acute leukemic transformation (AML) and reduces overall survival. In addition, thrombocytopenia in MDS limits the therapeutic efficacy of disease-modifying therapies, such as azacitidine or lenalidomide. Mechanisms of thrombocytopenia in MDS are complicated, involving suppression of megakaryocytic differentiation, enhanced apoptosis, and increased platelet destruction. Platelet transfusion is still the standard treatment option for MDS combined with thrombocytopenia. Recently, novel thrombopoietin (TPO) receptor agonists have showed curative effect in MDS patients in many clinical trials, including reducing bleeding events, decreasing dependency on platelet transfusions and increasing clinical benefits of disease-modifying therapies. Several clinical trials are ongoing to assess the efficacy and safety of novel TPO receptor agonists; the results would further help guide treatment for thrombocytopenia in MDS.

Myelodysplastic syndromes (MDS) comprises a heterogeneous group of myeloid clonal neoplasms characterized by peripheral cytopenia, dysplasia and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. We will summarize the proposed criteria for a classification of pre- MDS conditions as well as a proposed update for minimal diagnostic criteria of MDS in the present article.

HEV is a positive strand RNA virus containing 3 open reading frames(ORFs), while the function of its binding protein pORF3 is poorly understood. In our study, the interactive protein of the pORF3 from human liver cDNA library was screened by the SOS recruitment system, and the construction of the pSOS bait-ORF3 plasmid was identified. The expression of the pORF3 was analyzed by Western blotting, and the detection result of the self activation of bait protein was obtained as expected. Totally, 8 putative interacting proteins had been successively screened. Some of these cellular binding proteins of pORF3, especially the important immunological pathway kinase p110δ, may advance our understanding of the role in ORF3 protein of HEV, and the possible implications of these candidate proteins for the further research are discussed.